The goal of the Lymphoma Program's clinical research effort is to make the treatment of lymphoid malignancies more effective and specific, while also less toxic. Toward that goal, the program makes promising new therapies available to patients with a variety of lymphoid malignancies, in a carefully monitored setting, through clinical trials.
Current research focuses on targeting tumors with drugs directed against specific molecular targets in lymphoid malignancies, or with antibodies reactive against tumor cell surface proteins, alone or linked to radionucleotides. Another target of therapy is the tumor's "microenvironment" using inhibitors of angiogenesis (new blood vessel development) and stimulators of the immune response. Our team is also leading several clinical trials of CAR T-cell therapy for lymphoma.
Many members of the clinical research team also have active programs of laboratory-based investigation in lymphoid malignancies. Researchers work closely with other scientists within Harvard Medical School-affiliated institutions.
Chronic Lymphocytic Leukemia (CLL)
Watchful Waiting
Trial 17-105: A pilot study of a personalized neoantigen cancer vaccine with and without low-dose cyclophosphamide or pembrolizumab in treatment-naïve, asymptomatic patients with IGHV unmutated chronic lymphocytic leukemia
Principal Investigator: Inhye Ahn, MD
Trial 22-597: Randomized, phase 3 Study of early intervention with venetoclax and obinutuzumab versus delayed therapy with venetoclax and obinutuzumab in newly diagnosed asymptomatic high-risk patients with CLL: EVOLVE CLL study
Principal Investigator: Inhye Ahn, MD
Newly-Diagnosed
Trial 25-236: A Phase 1/2 open-label study to investigate the safety of sonrotoclax ramp-up schedule(s) in adult patients with hematological malignancies
Principal Investigator: Matthew Davids, MD, MMSc
Relapsed/Refractory
Trial 21-712: A multicenter, open-label, phase 2 study to evaluate the efficacy and safety of venetoclax- obinutuzumab retreatment in patients with recurring chronic lymphocytic leukemia
Principal Investigator: Matthew Davids, MD, MMSc
Trial 24-449: Randomized trial of venetoclax + rituximab/obin w/ or w/o roginolisib, novel PI3K-delta inhibitor
Principal Investigator: Jennifer Brown, MD, PhD
Trial 21-414: An open label phase 1a/b dose escalation followed by dose expansion safety and tolerability trial of CAP-100, A Humanized C-C-Chemokine receptor 7 antibody, administered as monotherapy in subjects with R/R chronic lymphocytic leukemia
Principal Investigator: Jennifer Brown, MD, PhD
Trial 24-444: A phase 1/2 open-label multi-centre master protocol to evaluate the safety and efficacy of AZD0486 monotherapy or in combination with other anticancer agents in participants with mature B-cell malignancies
Principal Investigator: Matthew Davids, MD, MMSc
Richter's Syndrome
Trial 23-429: A phase 2 study of glofitamab as monotherapy or in combination with atezolizumab and/or polatuzumab vedotin in patients with Richter's Syndrome
Principal Investigator: Christine Ryan, MD
Diffuse Large B-Cell Lymphoma (DLBCL)
Newly-Diagnosed
Trial 24-754: A phase 3, multicenter, randomized, open label study comparing the efficacy and safety of glofitamab (Ro7082859) in combination with polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-Chp) versus Pola-R-Chp in previously untreated patients with large b-cell lymphoma (SKYGLO)
Principal Investigator: David Qualls, MD
Trial 22-467: An adaptive phase 3, randomized, open-label, multicenter study to compare the efficacy and safety of axicabtagene ciloleucel versus standard of care therapy as first-line therapy in subjects with high-risk large B-cell lymphoma
Principal Investigator: Caron Jacobson, MD, MMSc
Transformed Follicular Lymphoma, Marginal Zone Lymphoma, or Other Transformed Indolent Lymphomas
Trial 22-606: A phase 2 study of glofitamab plus polatuzumab-R-CHP for patients with high-risk diffuse large B-cell lymphoma
Principal Investigator: Jennifer Crombie, MD
Relapsed/Refractory
Trial 24-253: A phase 1b open-label study to evaluate the safety and anti-cancer activity of loncastuximab tesirine in combination with other anti-cancer agents in patients with relapsed or refractory B-cell non-Hodgkin lymphoma
Principal Investigator: David Qualls, MD
Trial 24-006: A phase 1/2, multi-center, open-label, dose-finding study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of BMS-986458, alone and in combination with anti-lymphoma agents in participants with relapsed/refractory non-Hodgkin lymphomas (R/R NHL)
Principal Investigator: David Qualls, MD
Trial 22-451: A phase 2/3 multicenter, open-label, randomized, active-control study of zilovertamab vedotin (MK-2140) in combination with standard of care in participants with relapsed or refractory diffuse large B-cell lymphoma. (waveLINE-003)
Principal Investigator: Philippe Armand, MD, PhD
Follicular Lymphoma
Newly-Diagnosed
Trial 22-702: A phase 2 study of epcoritamab and rituximab for first-line treatment of follicular lymphoma
Principal Investigator: Reid Merryman, MD
Relapsed/Refractory
Trial 24-393: A phase 2 study of epcoritamab, zanubrutinib, and rituximab (EZR) for treatment of relapsed or refractory follicular lymphoma or marginal zone lymphoma
Principal Investigator: Reid Merryman, MD
Trial 24-006: A phase 1/2, multi-center, open-label, dose-finding study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of BMS-986458, alone and in combination with anti-lymphoma agents in participants with relapsed/refractory non-Hodgkin lymphomas (R/R NHL)
Principal Investigator: David Qualls, MD
Histiocyte Disorders
Trial 22-548: A phase 2 study to assess the safety and efficacy of cobimetinib in refractory Langerhans cell histiocytosis, LCH-associated neurodegenerative disease, and other histiocytic disorders
Principal Investigator: Eric Jacobsen, MD
Hodgkin Lymphoma
Newly-Diagnosed
Trial 23-553: A randomized phase 3 interim response adapted trial comparing standard therapy with immunooncology therapy for children and adults with newly diagnosed stage I and II classic Hodgkin lymphoma
Principal Investigator: Ann S. LaCasce, MD, MMSc
Relapsed/Refractory
Trial 22-121: A phase 2 study of brentuximab vedotin plus nivolumab without stem cell consolidation in patients with relapsed/refractory classical Hodgkin lymphoma
Principal Investigator: Philippe Armand, MD, PhD
Mantle Cell Lymphoma (MCL)
Newly-Diagnosed
Trial 24-654: A randomized phase 2 study of bendamustine, rituximab, cytarabine (AraC) induction with zanubrutinib (BRAZAN) followed by zanubrutinib/rituximab +/- sonrotoclax maintenance in treatment-naïve mantle cell lymphoma
Principal Investigator: Christine Ryan, MD
Trial 21-040: A phase 1/2 study of acalabrutinib, venetoclax, and obinutuzumab in patients with relapsed/refractory and previously untreated mantle cell lymphoma
Principal Investigator: Austin Kim, MD
Relapsed/Refractory
Trial 25-264: A Phase 3 Randomized Double-Blind Multicenter Study of Sonrotoclax Plus Zanubrutinib Versus Placebo Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma
Principal Investigator: Christine Ryan, MD
Trial 24-104: Pilot study of glofitamab and lenalidomide in patients with relapsed or refractory mantle cell lymphoma previously treated with a BTK inhibitor
Principal Investigator: Christine Ryan, MD
Trial 21-124: A multi-center single arm phase 2 study to evaluate the safety and efficacy of genetically engineered autologous cells expressing anti-CD20 and anti-CD19 specific chimeric antigen receptor in subjects with relapsed and/or refractory diffuse large B cell lymphoma
Principal Investigator: Caron Jacobson, MD, MMSc
Marginal Zone Lymphoma (MZL)
Relapsed/Refractory
Trial 24-393: A phase 2 study of epcoritamab, zanubrutinib, and rituximab (EZR) for treatment of relapsed or refractory follicular lymphoma or marginal zone lymphoma
Principal Investigator: Reid Merryman, MD
Primary Mediastinal Large B Cell Lymphoma (PMBCL)
Trial 23-179: A phase 2 trial of pembrolizumab in combination with chimeric antigen receptor therapy in patients with relapsed/refractory primary mediastinal B-cell lymphoma
Principal Investigator: Jennifer Crombie, MD
T-Cell Lymphoma
Relapsed/Refractory
Trial 22-248: Phase 1 multicenter study of ruxolitinib and duvelisib in relapsed or refractory T- or NK-cell lymphomas
Principal Investigator: Eric Jacobsen, MD
Trial 24-165: A phase 2 study evaluating the efficacy of ruxolitinib in patients with T-cell large granular lymphocytic leukemia (T-LGLL)
Principal Investigator: Eric Jacobsen, MD
Trial 24-459: An open-label, multi-center, non-randomized phase 1 dose escalation study to investigate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ONO-4685 given as monotherapy in patients with relapsed or refractory T-cell lymphoma
Principal Investigator: Eric Jacobsen, MD